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Abstract
Background Transcranial Doppler (TCD) is widely used
to detect and follow up cerebral vasospasm after sub-
arachnoid hemorrhage (SAH). Therapeutic hypothermia
might influence blood flow velocities assessed by TCD.
The aim of the study was to evaluate the effect of hypo-
thermia on Doppler blood flow velocity after SAH.
Methods In 20 patients treated with hypothermia (33)
due to refractory intracranial hypertension or delayed
cerebral ischemia (DCI), mean flow velocity of the middle
cerebral artery (MFVMCA) was assessed by TCD. Thirteen
patients were treated with combined hypothermia and
barbiturate coma and seven with hypothermia alone.
MFVMCA was obtained within 24 h before and after
induction of hypothermia as well as before and after
rewarming.
Results Hypothermia was induced on average 5 days after
SAH (range 1–12) and maintained for 144 h (range 29–270).
After hypothermia induction, MFVMCA decreased from
113.7 ± 49.0 to 93.8 ± 44.7 cm/s (p = 0.001). The
decrease was independent of SAH-related complications and
barbiturate coma. MFVMCA further decreased by 28.2 cm/s
between early and late hypothermia (p < 0.001). This sec-
ond decrease was observed in patients with DCI
(p < 0.001), but not in patients with intracranial hyperten-
sion (p = 0.715). Compared to late hypothermia, MFVMCA
remained unchanged after rewarming (65.6 ± 32.1 vs
70.3 ± 36.8 cm/s; p = 0.219). However, patients treated
with hypothermia alone showed an increase in MFVMCA
after rewarming (p = 0.016).
Conclusion Therapeutic hypothermia after SAH decrea-
ses Doppler blood flow velocity in both intracranial
hypertension and DCI cases. The results can be the effect
of hypothermia-related mechanisms or resolving cerebral
vasospasm during prolonged hypothermia.
Keywords Hypothermia  Subarachnoid hemorrhage 
Transcranial Doppler  Flow velocity  Cerebral blood flow
Introduction
Refractory high intracranial pressure (ICP) and delayed
cerebral ischemia (DCI) are the most important causes of
secondary brain injury after aneurysmal subarachnoid
hemorrhage (SAH) [1, 2]. Recent animal studies have
demonstrated that mild hypothermia (32–34 C) has the
potential to limit the extent of secondary brain injury by
reversing acute cerebral perfusion pressure-independent
hypoperfusion [3, 4], preventing brain edema formation [5,
6], and reducing cerebral vasospasm [7]. However, short-
term hypothermia during aneurysm surgery failed to
improve outcome in patients with good-grade SAH [8],
suggesting that only a carefully selected group of patients
with severe SAH suffering from intracranial hypertension
and/or DCI might benefit from prolonged hypothermia
treatment [9–11].
Although mild hypothermia likely interferes with a
variety of processes leading to secondary brain injury, the
most prevalent neuroprotective effect has been attributed to
the suppression of cerebral metabolic oxygen and glucose
demand [12, 13]. As a consequence, hypothermia has
consistently been associated with reduced cerebral blood
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flow (CBF) under physiological conditions [14, 15].
However, CBF measurements during hypothermia in
patients with acute brain injury are conflicting and the
existing data are mainly limited to patients with traumatic
brain injury [16–18]. The aim of this study was to evaluate
changes in blood flow velocities via transcranial Doppler
(TCD) sonography in patients with severe SAH who were
treated with prolonged hypothermia due to refractory high
ICP or DCI.
Materials and Methods
Patient Characteristics and Management
Between January 2007 and November 2010, 246 patients
with SAH were admitted to the Neurointensive Care Unit,
University Hospital Zurich. Of these, 46 patients with
hypothermia treatment due to refractory high ICP or DCI
were retrospectively identified from a prospective obser-
vational database approved by the local ethics committee.
Thirty-eight of them underwent TCD examination within
24 h before induction of hypothermia. Patients with
induction of hypothermia during already initiated barbitu-
rate coma (n = 4) or immediately after endovascular
treatment of cerebral vasospasm (n = 14) were excluded
from the study.
Patients were managed according to a standardized pro-
tocol [10, 19]. Treatment of high ICP (>20 mmHg)
consisted of cerebrospinal fluid drainage and osmotherapy
(mannitol 20 %, hypertonic NaCl-hydroxyethyl-starch
solution). Primary decompressive craniectomy was per-
formed if signs of severe brain swelling were present during
or immediately after aneurysm surgery and secondary de-
compressive craniectomy if elevated ICP was refractory to
maximal medical treatment. The presence of DCI was clin-
ically defined as secondary neurological deficit or
radiological evidence of a delayed cerebral infarction.
Cerebral vasospasm was confirmed or ruled out by regular
catheter angiography. All patients were treated with oral
nimodipine. Hypertensive therapy (systolic blood pressure
>150 mmHg) was initiated if signs of DCI were apparent. If
patients did not improve, balloon angioplasty and/or super-
selective papaverine infusion were performed. Hypothermia
alone or in combination with barbiturate coma was applied as
treatment of last resort if high ICP or DCI were refractory
despite the above-mentioned treatment.
Hypothermia (target temperature 33.0–33.9 C) was
induced and maintained by endovascular cooling (Quat-
troTM, Zoll Medical, Chelmsford, USA). In patients
without contraindications for barbiturates, hypothermia
was induced simultaneously with barbiturate coma. The
thiopental loading dose was 10 mg/kg, followed by a
continuous infusion adapted to an electroencephalographic
(EEG) burst suppression pattern. Hypothermia and barbi-
turate coma were maintained until ICP normalized, DCI
resolved or severe side effects occurred. Rewarming was
performed ICP-controlled and no faster than 1 C per 24 h.
Physiological Measurements
The following physiological parameters were obtained
within 24 h before induction of hypothermia (Pre-HT,
>35 C), after reaching hypothermia (Early-HT, 33 C),
before rewarming (Late-HT, 33 C), and after rewarming
to normothermia (Post-HT, >35 C): mean flow velocity
in both middle cerebral arteries (MFVMCA), ICP, body core
temperature (BCT), mean arterial pressure (MAP), arterial
carbon dioxide tension (PaCO2), and hematocrit (HCT).
Measurement values were obtained on average 7 h before
hypothermia, 15 h after reaching hypothermia and 14 h
before rewarming. Post-treatment values were available in
14 patients and obtained on average 9 h after reaching
normothermia.
Bilateral MFVMCA was measured by transcranial color-
coded duplex sonography with a 2-MHz probe (ACUSON
2000TM, Siemens Healthcare, Germany). TCD examinations
were performed daily by an independent neuroradiologist
according to the method developed by Aaslid et al. [20]. The
best signal obtained was insonated at a depth between 50 and
60 mm, and the mean flow velocity recorded from serial
TCD. In healthy adults average MFVMCA is in the range of
73 ± 25 cm/s [21]. All patients had a ventricular catheter
(Neurovent, Raumedic AG, Germany) or intraparenchy-
matous probe (Neurovent-P, Raumedic AG, Germany or
BactisealTM, Codman, Johnson & Johnson; USA) for con-
tinuous ICP monitoring. BCT and MAP were measured via a
thermistor-tipped femoral arterial catheter. Blood gas ana-
lysis for determination of PaCO2 and HCT was performed
via the same arterial line.
Statistical Analysis
Mean values of physiological parameters were compared
by paired t test. Patients were classified according to spe-
cific SAH-related complications (ICP- vs DCI-group) and
treatment protocol (combined hypothermia and barbiturate
coma (cHTBC-group) versus hypothermia alone (HT-
group)). Intergroup differences were compared by Mann–
Whitney U test and Fisher’s exact test. The relation
between mean differences in MFVMCA and MAP, PaCO2,
and ICP were determined by linear regression analysis with
calculation of the Pearson correlation coefficient. A p value
<0.05 was considered statistically significant.
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Results
A total of 20 patients were included in this study. Clinical and
treatment characteristics are summarized in Table 1. The
overall incidence of severe SAH according to the World Fed-
eration of Neurological Surgeon (WFNS) grades 4–5 and
Fisher scores 3–4 was 50 and 95 %, respectively. Hypothermia
was induced on average 5 days after SAH (range 1–12) and
maintained for 144 h (range 29–270). The overall in-hospital
mortality rate was 15 %. Hypothermia was induced earlier in
the ICP-group compared to the DCI-group (p = 0.002).
Otherwise, there were no significant intergroup differences
with regards to patients’ age, admission scores, specific SAH-
related complications, treatment protocol, duration of hypo-
thermia, and outcome. The 12-month outcome according to the
Glasgow Outcome Scale (GOS) showed favorable outcome
(GOS 4–5) in 40 % (n = 8), severe disability (GOS 3) in 35 %
(n = 7), and death (GOS 1) in 25 % (n = 5).
Effects of Hypothermia on Physiological Parameters
A total of 148 MFVMCA values were available from
bilateral TCD examinations. MFVMCA was available in all
patients before hypothermia (40 values), early after
reaching hypothermia (40 values), and before rewarming
during late hypothermia (40 values). After rewarming to
normothermia MFVMCA was available in 14 patients (28
values). The mean values of physiological parameters are
summarized in Table 2. Mean MFVMCA decreased signif-
icantly by 19.8 cm/sec after hypothermia induction
(p = 0.001) and remained unchanged after rewarming
(p = 0.219) (Fig. 1). Likewise, mean ICP decreased by
5.6 mmHg after hypothermia induction (p < 0.001) and
remained unchanged after rewarming (p = 0.176). There
were no significant changes in mean MAP, PaCO2, and
HCT after hypothermia induction and after rewarming.
There was no significant correlation between changes in
MFVMCA and MAP (95 % CI -0.3 to 0.4, p = 0.749) and
PaCO2 (95 % CI -0.1 to 0.5, p = 0.204). The correlation
between changes in MFVMCA and ICP was statistically
significant (95 % CI 0.0–0.6, p = 0.048).
The following changes in physiological parameters were
observed between early and late hypothermia: MFVMCA
decreased by 28.2 cm/s (95 % CI -43.6 to -12.3,
p = 0.0007) and PaCO2 increased by 0.6 kPa (95 % CI
0.4–0.9, p = 0.0002). There were no significant changes in
Table 1 Clinical and treatment characteristics stratified by specific SAH-related complications and treatment protocol
Total
(n = 20)
ICP-group
(n = 9)
DCI-group
(n = 11)
p value cHTBC-group
(n = 13)
HT-group
(n = 7)
p value
Age, years (mean ± SD) 55.8 ± 9.1 56.8 ± 8.9 55.0 ± 9.6 0.647 58.1 ± 8.4 51.6 ± 9.4 0.121
WFNS grade
1–3, n (%) 10 (50) 4 (44) 5 (50) 1.000 7 (54) 3 (43) 1.000
4–5, n (%) 10 (50) 5 (56) 5 (50) 6 (46) 4 (57)
Fisher grade
1–2, n (%) 1 (5) 1 (11) 0 (0) 0.450 1 (8) 0 (0) 1.000
3–4, n (%) 19 (95) 8 (89) 11 (100) 12 (92) 7 (100)
Specific complications
Intracranial hypertension, n (%) 9 (45) – – – 5 (38) 4 (57) 0.642
Delayed cerebral ischemia, n (%) 11 (55) 8 (62) 3 (43)
Treatment protocol
Hypothermia and barbiturate coma, n (%) 13 (65) 5 (56) 8 (73) 0.642 – – –
Hypothermia, n (%) 7 (35) 4 (44) 3 (27)
Hypothermia
Induction; days after SAH (median (range)) 5 (1–12) 3 (1–6) 9 (3–12) 0.002 5 (2–12) 3 (1–12) 0.360
Time until BCT < 34 C, hours (median
(range))
2 (1–31) 2 (2–31) 2 (1–5) 0.204 3 (1–19) 2 (2–31) 0.199
Duration of BCT 33 C, hours (median (range)) 144 (29–270) 150 (29–270) 146 (89–183) 1.000 154 (112–249) 107 (29–270) 0.088
Time until BCT > 35 C, hours (median
(range))
41 (10–113) 37 (10–112) 42 (22–113) 0.732 41 (22–113) 44 (10–110) 0.968
Outcome at hospital discharge
Survivors, n (%) 17 (85) 8 (89) 9 (82) 1.000 11 (85) 6 (86) 1.000
Died, n (%) 3 (15) 1 (11) 2 (18) 2 (15) 1 (14)
ICP intracranial pressure, DCI delayed cerebral ischemia, HT hypothermia, cHTCB combined hypothermia and barbiturate coma, WFNS World
Federation of Neurological Surgeons, SAH subarachnoid hemorrhage, BCT body core temperature
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ICP (95 % CI -9.8 to 13.5, p = 0.715), MAP (95 % CI
-6.3 to 9.5, p = 0.680), and HCT (95 %CI -1.7 to 1.2,
p = 0.723) between early and late hypothermia.
Effect of Hypothermia on MFVMCA According to
Patient Subgroups
Mean MFVMCA for the patients’ subgroups according to
specific SAH-related complications and treatment protocol
are shown in Table 3. Hypothermia was induced due to
refractory high ICP in 9 patients and DCI in 11 patients.
MFVMCA before hypothermia and during early hypother-
mia was significantly higher in the DCI-group compared to
the ICP-group (p = 0.002 and 0.003, respectively). After
induction of hypothermia, MFVMCA significantly
decreased in both the ICP-group (p = 0.016) and the DCI-
group (p = 0.023, Fig. 2a). Between early and late hypo-
thermia, MFVMCA significantly decreased in the DCI-
group (95 % CI 25.6–72.8, p < 0.001), but remained
unchanged in the ICP-group (95 % CI -14.6 to 10.4,
p = 0.724). MFVMCA remained unchanged after rewarm-
ing to normothermia in both, the ICP-group (p = 0.564)
and the DCI-group (p = 0.198).
Thirteen patients were treated with combined hypothermia
and barbiturate coma (cHTBC-group) and 7 patients with
hypothermia alone (HT-group) due to contraindications for
barbiturates. There were no significantdifferences in MFVMCA
between both groups during the study (Table 3). After induc-
tion of hypothermia, MFVMCA significantly decreased in both
the cHTBC-group (p = 0.020) and the HT-group (p = 0.013,
Fig. 2b). MFVMCA further decreased between early and late
hypothermia in the cHTBC-group (95 %CI 3.9–45.7,
p = 0.022) and the HT-group (95 % CI 2.6–21.6, p = 0.017).
After rewarming to normothermia, MFVMCA increased in the
HT-group (p = 0.016), but remained unchanged in the
cHTBC-group (p = 0.822). In 10 patients barbiturate admin-
istration was discontinued before rewarming (on average 48 h
before, range 16–164) and in 3 patients after rewarming (on
average 60 h post rewarming, range 30–87).
Discussion
The goal of this study was to evaluate the effect of hypo-
thermia on blood flow velocity in patients with SAH via
TCD. Mean differences in MFVMCA were used to estimate
relative changes in CBF, as previously reported [22–24].
However, the expected linear relationship between
MFVMCA and CBF only applies if the angle of isonation
and blood vessel diameter remains constant
(MFVMCA = CBF/angle of isonation * vessel diameter).
The variations in the angle of isonation were minimized by
using transcranial color-coded duplex sonography, a tech-
nique reported to improve consistency and accuracy of
TCD [25]. In addition the diameter of the proximal seg-
ment of the middle cerebral artery has been shown to
remain constant during moderate changes in MAP and
PaCO2 [26, 27]. However, vasospasm of the middle cere-
bral artery is frequently observed after SAH and may
Table 2 Changes in mean values of physiological parameters in all patients
Pre-HT (BCT
>35 C)
Early-HT (BCT
33 C)
p value
(95 % CI)
Late-HT
(BCT 33 C)
Post-HT
(BCT >35 C)
p value
(95 % CI)
MFVMCA (cm/sec) 113.6 ± 49.0 93.8 ± 44.7 0.001 (-31.2 to -8.4) 65.6 ± 32.1 70.3 ± 36.8 0.219 (-4.2 to 17.6)
ICP (mmHg) 17.2 ± 6.2 11.6 ± 6.3 0.0002 (-7.8 to -2.9) 13.8 ± 4.3 16.5 ± 4.3 0.176 (-1.5 to 7.4)
MAP (mmHg) 105.5 ± 16.7 108.4 ± 15.3 0.395 (-4.1 to 9.9) 109.3 ± 16.1 108.3 ± 11.8 0.735 (-7.1 to 5.1)
PaCO2 (kPa) 4.9 ± 0.4 4.8 ± 0.4 0.073 (-0.3 to 0.02) 5.4 ± 0.4 5.3 ± 0.5 0.300 (-0.3 to -0.1)
HCT (%) 30.3 ± 2.1 30.5 ± 2.4 0.582 (-0.7 to 1.2) 29.9 ± 2.9 29.3 ± 1.3 0.125 (-2.3 to 0.3)
MFVMCA mean flow velocity in the middle cerebral artery, ICP intracranial pressure, MAP mean arterial pressure, PaCO2 arterial carbon dioxide
tension, HCT hematocrit, HT hypothermia, BCT body core temperature, CI confidence interval
Fig. 1 The effect of hypothermia on mean flow velocity in the
middle cerebral artery (MFVMCA) in all patients. Values are
expressed as mean and 95 % CI. Dashed lines indicate lower and
upper physiological limits of MFVMCA values according to Krejza
et al. [21]. Asterisk indicates statistical significant difference between
monitoring periods (paired t test, p value <0.05)
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increase MFVMCA, as confirmed previously [28]. If TCD is
performed serially after SAH there is usually a steady rise
in blood flow velocity with peak values around 1 week
from SAH and recovery back to normal values over
another week, reflecting the time course of pathological
changes in arteries occurring during cerebral vasospasm
[29]. Therefore, the results of this study need to be inter-
preted with particular care, as mean differences in
MFVMCA might indicate (1) relative changes in CBF and/
or (2) dynamic changes during cerebral vasospasm.
In the current study, the decrease in MFVMCA after
induction of hypothermia was independent of the indica-
tion for hypothermia (high ICP or DCI), as well as from
blood pressure, PaCO2, and hematocrit. This suggests that
a lower body temperature (33 C) itself is an important
determinant of reduced blood flow velocities and possibly
reflects lower CBF. Simultaneous induction of barbiturate
coma may partly explain the decrease in MFVMCA in our
patients. Barbiturates substantially reduce cerebral metab-
olism and, as a consequence, can lead to a decrease in CBF
[30, 31]. Furthermore, hypothermia prolongs the duration
of barbiturate-induced burst suppression pattern on EEG
[32], possibly reflecting the unchanged MFVMCA after
rewarming in patients with combined hypothermia and
barbiturate coma. However, decreased MFVMCA after
induction of hypothermia together with increased MFVMCA
after rewarming in patients treated with hypothermia alone
may suggest an independent temperature effect on CBF.
Although the occurrence of cerebral vasospasm very likely
influenced the absolute MFVMCA values, relative changes
in MFVMCA after both induction of hypothermia (on
average 5 days after SAH) and rewarming to normothermia
(on average 13 days after SAH) were opposite to the time
course of pathological changes in arteries after SAH.
Finally, the study confirms previous reports on ICP
reductions during hypothermia in patients with acute brain
injury [16–18, 33]. In order to avoid rebound of ICP,
rewarming should be performed ICP-controlled and no
faster than 0.5–1 C per 24 h. Furthermore, an abnormal
increase in Doppler blood flow velocities during rewarming
may serve as an index in the prediction of acute brain
swelling, undermining the use of TCD as a rapid and non-
Table 3 Mean flow velocity in the middle cerebral artery (MFVMCA (cm/s)) according to patients’ subgroups
Pre-HT (BCT
>35 C)
Early-HT (BCT
33 C)
p value
(95 % CI)
Late-HT (BCT
33 C)
Post-HT
(BCT >35 C)
p value
(95 % CI)
ICP-group (n = 9) 87.2 ± 35.8 69.7 ± 29.4 0.016 (3.7 to 31.3) 67.4 ± 26.9 70.3 ± 26.7 0.564 (-18.0 to 31.3)
DCI-group (n = 11) 135.2 ± 48.3 113.5 ± 45.8 0.023 (3.3 to 40.1) 64.3 ± 36.0 70.4 ± 43.8 0.198 (-3.5 to 15.7)
p value 0.002 0.003 0.487 0.501
cHTBC-group (n = 13) 107.7 ± 39.4 87.9 ± 37.2 0.020 (3.5 to 36.1) 64.2 ± 28.6 65.1 ± 35.3 0.822 (–16.6 to 20.6)
HT-group (n = 7) 124.6 ± 63.4 104.8 ± 55.9 0.013 (4.9 to 34.6) 68.0 ± 38.5 77.3 ± 39.1 0.016 (8.0 to 65.6)
p value 0.600 0.379 0.928 0.246
ICP indicates intracranial pressure, DCI delayed cerebral ischemia, cHTCB combined hypothermia and barbiturate coma, HT hypothermia, BCT
body core temperature, CI confidence interval
Fig. 2 The effect of hypothermia on mean flow velocity in the
middle cerebral artery (MFVMCA) according to patients’ subgroups. a
Changes in MFVMCA in patients with refractory high intracranial
pressure versus delayed cerebral ischemia. b Changes in MFVMCA in
patients treated with combined hypothermia and barbiturate coma
versus hypothermia alone. Values are expressed as mean and 95 %
CI. Dashed lines indicate lower and upper physiological limits of
MFVMCA values according to Krejza et al. [21]. Asterisk indicates
significant difference in the ICP- or cHTBC-group, hash indicates
significant difference in the DCI- or HT-group
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invasive method to monitor cerebral hemodynamics during
hypothermia [34].
Hypothermia is a therapeutic approach that likely
interferes with a variety of processes leading to secondary
brain injury, of these the suppression of cerebral metabolic
rates of oxygen and glucose has been regarded as its most
prevalent neuroprotective effect [12]. As a consequence, it
is well known that hypothermia can lead to a reduction in
CBF under physiological conditions [13, 14]. In juvenile
pigs on cardiopulmonary bypass, Ehrlich et al. [15] dem-
onstrated that flow-metabolism coupling was maintained
and cerebrovascular resistance increased when body tem-
perature was lowered from 37 to 28 C. The findings of the
current study support the physiological model of reduced
CBF during hypothermia. Furthermore, the significant
correlation between changes in MFVMCA and ICP might
enhance the concept of increased cerebrovascular resis-
tance during hypothermia [35]. Although the exact
mechanisms of hypothermia-related ICP reductions remain
to be elucidated, increased cerebrovascular resistance
leading to reduced cerebral blood volume, and thus to
reduced ICP, has been demonstrated previously [36]. Given
the lack of controlled studies, no general recommendation
for therapeutic hypothermia after SAH can currently be
made. However, favorable outcome in 40 % of our patients
may further support previous reports that patients with
most severe SAH having refractory intracranial hyperten-
sion or DCI may benefit from prolonged hypothermia
treatment [9, 10].
Hypothermia-related CBF reductions after acute brain
injury are consistent with most [16, 17, 37, 38] but not all
[18, 39] clinical studies, a possible reflection of the time
point of hypothermia induction and different causes of pri-
mary brain injury. Shiozaki et al. [17] described a reduction
in CBF by 15.4 ml/100 g/min during hypothermia in 5
patients developing refractory intracranial hypertension
within 48 h after traumatic brain injury. On the other hand,
Metz et al. [18] reported no change in CBF in 10 patients
with traumatic brain injury after induction of hypothermia
immediately after hospital admission. In our study, hypo-
thermia was induced on average 5 days after SAH, when
intracranial hypertension or DCI was refractory to conven-
tional treatment. This might suggest that these results are
independent of the impact of primary brain injury in the
majority of patients, and thus might reflect true hypothermia-
related changes on cerebral hemodynamics.
The effect of hypothermia on CBF after SAH is dis-
cussed controversially. Thome et al. [3] and Schubert et al.
[4] demonstrated that hypothermia, induced before or
immediately after cisternal blood injection in rats,
improves CBF during cerebral perfusion pressure-inde-
pendent hypoperfusion. In contrast, To¨ro¨k et al. [40]
reported no change in CBF when hypothermia was induced
up to 3 h after SAH using the endovascular perforation
model in rats. The authors concluded that different sever-
ities of SAH in different experimental models might have
contributed to these contradicting results. So far, two
clinical reports have described CBF during hypothermia.
Using positron emission tomography, Kawamura et al. [41]
reported a decrease in CBF by 37–44 % during hypother-
mia in 5 patients with poor-grade SAH. However, the
results are difficult to interpret as the CBF measurements
were compared to normal values from normothermic vol-
unteers. Furthermore, globally reduced CBF after SAH is
also observed in normothermic patients [42, 43]. In the
second study, Nagao et al. showed by means of single
photon emission tomography that CBF decreased by
6.4 ml/100 g/min after induction of hypothermia and
increased by 10.8 ml/100 g/min after rewarming in a total
of 7 patients with cerebral vasospasm causing delayed
ischemic neurological deficits. The authors noted that the
change in CBF was detected in the region of cerebral
vasospasm and CBF measurements were only performed if
the patients’ condition allowed for technically difficult
imaging studies. Therefore, the distinction between hypo-
thermia- and vasospasm-related effects on CBF is difficult.
For the current study routine TCD was used to evaluate
relative changes in CBF during specific monitoring peri-
ods, i.e., before, during, and after hypothermia.
Nevertheless, the dynamic changes during cerebral vaso-
spasm are very likely to influence MFVMCA in particular
during prolonged hypothermia.
Cerebral vasospasm is considered an important cause of
DCI and can partly be explained by the mismatch between
vasodilatatory and -constrictor substances as well as detri-
mental effects of SAH-related inflammatory reactions [44].
Animal studies have shown the potentially beneficial effects
of hypothermia on cerebral vasospasm [3, 4, 7]. Further-
more, we previously demonstrated the attenuation of
inflammatory reactions during combined hypothermia and
barbiturate coma in patients with severe SAH [45]. The
strong correlation between elevated blood flow velocities
from TCD and radiological evidence of cerebral vasospasm
has been reported previously [28, 46]. Accordingly, we
observed higher MFVMCA before and during early hypo-
thermia in patients with DCI (7 of 11 patients with MCA
vasospasm) compared to patients with intracranial hyper-
tension. As mentioned above, the rapid changes in MFVMCA
after both hypothermia induction and rewarming are unli-
kely to reflect the pathological changes in arteries occurring
during cerebral vasospasm. However, the decrease in
MFVMCA during prolonged hypothermia (on average 144 h)
might suggest resolved cerebral vasospasm in the subgroup
of patients with DCI. These findings undermine the impor-
tance of carefully interpreting TCD findings in SAH patients
with hypothermia, because changes in Doppler blood flow
260 Neurocrit Care (2014) 20:255–262
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velocity might reflect hypothermia-related changes in CBF
and/or the dynamic changes during cerebral vasospasm.
Additional temperature effects on MFVMCA during pro-
longed hypothermia in the current study are unlikely, based
on the tight temperature control (33.0–33.9 C) using
endovascular cooling [47].
The following limitations of this study need to be con-
sidered. First, the sample size of patients’ subgroups is
small. Second, while hyperemia with high absolute CBF
values has to be considered as differential diagnosis to
cerebral vasospasm in patients with elevated flow veloci-
ties, the flow velocity in the extracranial internal carotid
artery is not routinely measured at our institution, thus, the
Lindegaard index could not be calculated. However, cere-
bral vasospasm was confirmed or excluded by catheter
angiography in all patients. In addition, we investigated the
mean differences in MFVMCA during specific monitoring
periods, thus avoiding the difficulties of interpreting iso-
lated TCD findings. Finally, we could not establish
hypothermia-related changes in cerebral metabolic
demands, although all patients were treated with bilateral
extended cerebral monitoring (brain tissue oxygen tension
and microdialysis) during prolonged hypothermia treat-
ment. However, hypothermia was induced as early and fast
as possible if SAH-specific complications were refractory
to other therapies, a time at which extended cerebral
monitoring was not installed in majority of patients.
Conclusion
Therapeutic hypothermia after SAH reduces MFVMCA in
both intracranial hypertension and DCI cases. The results
might reflect the physiological model of reduced CBF at
lower body temperatures and undermine the use of TCD as
a rapid and non-invasive method to monitor cerebral
hemodynamics during hypothermia treatment. Further
studies are needed to investigate flow-metabolism coupling
during hypothermia in patients with SAH.
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